April 15, 2010 - Targeting microRNA improves insulin resistance and glucose tolerance in mouse models of diabetes – Regulus Therapeutics Inc. announced that new data from its metabolic disease program were presented at the “Diabetes” Keystone Symposium held April 12-17 in Whistler, British Columbia. The new pre-clinical research findings showed that therapeutic oligonucleotides targeting microRNA are able to improve insulin resistance and normalize plasma glucose in mouse models of diabetes while having no significant effect on glucose or insulin levels in normal mice. The increased incidence of diabetes is a growing threat to global health, and microRNA therapeutics represent a promising strategy for the discovery and development of novel anti-diabetic agents.
“Diabetes is a multi-factoral disease that results in disruption of the metabolic system. microRNA therapies that can modulate pathways of disease rather than single molecular targets represent a novel approach for diabetes,” ...
......About Regulus Therapeutics Inc.
Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative new medicines based on microRNAs. Regulus is targeting microRNAs as a new class of therapeutics by working with a broad network of academic collaborators and leveraging oligonucleotide drug discovery and development expertise from its founding companies Alnylam Pharmaceuticals (Nasdaq:ALNY) and Isis Pharmaceuticals (Nasdaq:ISIS).... Regulus Therapeutics' Press Release - Alnylam Pharmaceuticals' Press Release - Isis Pharmaceuticals' Press Release -
